Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition

Clin Lung Cancer. 2020 Nov;21(6):e544-e546. doi: 10.1016/j.cllc.2020.05.006. Epub 2020 May 12.

Authors

Georgios Tsakonas¹, Vitali Grozman², Simon Ekman³

Affiliations

¹ Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: georgios.tsakonas@ki.se.
² Department of Thoracic Radiology, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
³ Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

PMID: 32522509
DOI: 10.1016/j.cllc.2020.05.006

No abstract available

Keywords: BRAF V600E; Brain metastases; Dabrafenib; Non–small-cell lung cancer; Trametinib.

Publication types

Case Reports

MeSH terms

Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / pathology
Adenocarcinoma of Lung / therapy*
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Brain Neoplasms / genetics
Brain Neoplasms / secondary
Brain Neoplasms / therapy*
Combined Modality Therapy
Humans
Imidazoles / administration & dosage
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
MAP Kinase Kinase 1 / antagonists & inhibitors*
Mutation*
Oximes / administration & dosage
Prognosis
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics*
Pyridones / administration & dosage
Pyrimidinones / administration & dosage
Radiosurgery / methods

Substances

Imidazoles
Oximes
Pyridones
Pyrimidinones
trametinib
BRAF protein, human
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase 1
MAP2K1 protein, human
dabrafenib